Jiangsu Alpha Pharmaceutical Co., Ltd. is a comprehensive national high-tech enterprise focused on advanced pharmaceutical intermediates, APIs, chemical preparations, biocatalysis and biological fermentation. The company has built a diversified product pipeline covering statin series, SGLT‑2 inhibitor intermediates, anti‑tumor, anti‑asthma and anticoagulant intermediates. Its core portfolio includes Atorvastatin Calcium and Intermediates, Rosuvastatin Calcium and Intermediates, Pitavastatin Calcium Intermediates, Dapagliflozin Intermediates, Empagliflozin Intermediates, Ezetimibe Intermediates, Dabigatran Intermediates, Montelukast Intermediate, Abiraterone Intermediate, Ibrutinib Intermediate and Linagliptin Intermediate. With solid industrial foundation in statin products, it stands as an important global supplier of statin intermediates.
Recently, the in-house R&D team has successfully completed systematic iteration and full-scale process verification for the synthetic route of Atorvastatin Calcium and its key chiral intermediates. The team re-evaluated the whole synthetic sequence, redesigned the catalytic framework and restructured the workflow of asymmetric reduction, protection and deprotection. Part of the traditional heavy-metal catalysis steps are replaced with high-selectivity biocatalytic modules, which deliver obvious advantages in stereocontrol. The optimized route lifts overall reaction yield, improves chiral purity and suppresses the generation of stubborn related impurities that are difficult to remove in downstream purification.
The upgraded process also brings notable improvements to environmental performance. The reformed reaction and separation scheme effectively cuts down organic solvent consumption and wastewater discharge, aligning with the company’s long-term roadmap of green fine chemical manufacturing. Every batch of intermediate is subjected to full analytical testing via HPLC, GC and chiral chromatography. Complete batch production records, raw material traceability documents and analytical test reports are retained throughout the whole manufacturing cycle, supporting full traceability for quality review and regulatory inspection. The company applies unified quality standards across all intermediate platforms, and implements independent production segregation to avoid cross-contamination between different chiral molecules.
This technical upgrade further consolidates the company’s leading position in statin pharmaceutical building blocks. It enables Jiangsu Alpha Pharmaceutical to provide downstream API developers with highly stable, well-reproducible intermediate materials. Reliable intermediate supply helps clients advance the formulation study, impurity profiling and registration work of lipid-lowering drugs, laying a solid foundation for both clinical development and subsequent commercial production of atorvastatin calcium APIs. The company will continue to carry out process optimization across its whole intermediate portfolio, expanding mature green biocatalysis experience to other statin and hypoglycemic intermediate projects to serve global pharmaceutical R&D partners.